It is suggested that t-cfDNA could potentially serve as an early biomarker for identifying pregnancies at elevated risk of FGR and adverse pregnancy outcomes and is limited by statistical power, warranting cautious interpretation.
Abstract
Background/Objectives: Noninvasive prenatal screening (NIPS) fails in approximately 0.2% of cases due to high maternal plasma total cell-free DNA (t-cfDNA) concentration (≥0.6 ng/µL) confirmed after two DNA extraction attempts. The clinical implications of this quality control metric for fetal growth restriction (FGR) remain unknown. Methods: This retrospective cohort study, conducted in a major prenatal diagnosis center in China, involved pregnant women who underwent noninvasive prenatal screening (NIPS) between 2019 and 2024. From a total of 73,636 pregnancies, 102 singleton pregnancies with excessively high t-cfDNA concentration (≥0.6 ng/µL upon retesting) leading to NIPS failure were compared with 396 matched controls (t-cfDNA < 0.6 ng/µL) after propensity score matching. The primary outcome was FGR, defined as estimated fetal weight or abdominal circumference below the 10th percentile for gestational age. Results: In the matched cohort, FGR occurred in 26.47% of the high-concentration group versus 9.60% of controls (OR = 3.27, 95% CI: 1.45–7.41, p = 0.004). The high-concentration group also had lower gestational age at delivery (37.44 vs. 38.48 weeks, p < 0.001) and higher preterm birth rates (18.63% vs. 7.57%, p = 0.025). Subgroup analyses for severe and FGR first detected before 32 weeks were exploratory and limited by statistical power, warranting cautious interpretation. Conclusions: An excessively high maternal t-cfDNA concentration in early pregnancy shows a significant association with FGR and adverse pregnancy outcomes. These findings suggest that t-cfDNA could potentially serve as an early biomarker for identifying pregnancies at elevated risk of FGR. Further validation of our findings in prospective studies is required to establish its clinical utility.
The fetal fraction (FF) of cell-free DNA determines the reliability of non-invasive prenatal testing (NIPT); whether first-trimester placental biomarkers add information beyond maternal factors is unclear. We linked NIPT samples from a single fetal medicine center over ten years (1162 pregnancies) to first-trimester sc...
M. Mureșan, M. Mureșan, D. Biriș et al.· Life· 0 citations
OBJECTIVE
To evaluate the performance of low-depth non-invasive prenatal testing (NIPT) using cell-free DNA enrichment for detecting fetal copy number variations (CNVs) and to assess its clinical utility.
METHODS
A retrospective analysis was conducted on 86,012 pregnant women who underwent NIPT with size-selective ce...
Xiao-Yi Liu, Xian-Zhen Cao, Liang Hu et al.· Prenatal Diagnosis· 0 citations
OBJECTIVE
Cell-free DNA whole-genome screening (cfDNA-WG) is offered at our institution to patients with abnormal fetal ultrasound findings who decline diagnostic testing. We describe the cfDNA-WG performance in this clinical population.
METHODS
We conducted a retrospective cohort study of singleton pregnancies with...
A. Prior, Lauren J. Taylor, Nick P. Guilda et al.· Prenatal Diagnosis· 0 citations
The parameters requiring modification in a much larger series, and with pregnancy outcome data, are highlighted, before prospective evaluation of combined PlGF and FF screening for PE.
M. L. Rabbi, H. Meiri, R. Maymon et al.· Archives of Gynecology and O...· 0 citations
Prenatal cell‐free DNA screening is widely used to assess the risk of fetal trisomy 21, 18, and 13. Although commercial and laboratory‐developed tests (LDTs) show high accuracy in validation studies, real‐world longitudinal performance data are lacking.
Armelle Duquenne, N. Brison, I. Parijs et al.· Prenatal Diagnosis· 0 citations
These results demonstrate cfMeDIP-seq’s ability to enrich for cell-free placental DNA and characterize cell-free DNA methylation signatures of pregnancies complicated by IUGR and highlight the potential of cell-free placental DNA for monitoring pregnancy health.
Keaton W Smith, Natalie Yuen, Shu Y. Shen et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.